Mangoceuticals signs business combination deal with Nuclea Energy

Morpheus is in conceptual design, targeted at 3.5 MWe to 50 MWe output, with an 18-month roadmap toward regulatory and commercial readiness.

Nuclea shareholders will receive exchangeable shares, convertible one-for-one into Mangoceuticals common stock, with economics and votes designed to match.

Rights tied to the exchangeable shares will be capped at 19.99% of Mangoceuticals shares outstanding at closing until stockholder and Nasdaq approvals.

Mangoceuticals struck a business combination agreement with Nuclea Energy, an advanced nuclear developer focused on the lead-cooled Morpheus microreactor.

A newly formed Mangoceuticals subsidiary will merge with Nuclea, leaving Nuclea as an indirect wholly owned subsidiary of Mangoceuticals.